André Robidoux
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Risks and Factors
- Colorectal Cancer Surgical Treatments
- Cancer survivorship and care
Papers in
-
- Breast Cancer Treatment Studies 55
- Oncology 31
- Cancer Risks and Factors 8
- Cancer survivorship and care 7
- HER2/EGFR in Cancer Research 7
- Bone health and treatments 5
- Co-authors
- Norman Wolmark (36 shared papers)Donald Lawrence Wickerham (11 shared papers)Bernard Fisher (10 shared papers)Joseph P. Costantino (12 shared papers)Richard G. Margolese (12 shared papers)James N. Atkins (8 shared papers)Eleftherios P. Mamounas (22 shared papers)Sam Wieand (2 shared papers)
- Journals
- Journal of Clinical Oncology (17 papers)Breast Cancer Research and Treatment (13 papers)The Lancet Oncology (7 papers)JNCI Journal of the National Cancer Institute (6 papers)Clinical Breast Cancer (5 papers)
- Partner nations
- CanadaUnited StatesSwitzerland
In The Last Decade
André Robidoux
108 papers receiving 22.8k citations
André Robidoux's Hit Papers
Peers
Comparison fields: 5 of 141
- Cancer Research 11.7k
- Oncology 5.5k
- Genetics 3.7k
- Pathology and Forensic Medicine 1.7k
- Internal Medicine 201
Countries citing papers authored by André Robidoux
This map shows the geographic impact of André Robidoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by André Robidoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites André Robidoux more than expected).
Fields of papers citing papers by André Robidoux
This network shows the impact of papers produced by André Robidoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by André Robidoux. The network helps show where André Robidoux may publish in the future.
Co-authors
The 25 scholars most cited alongside André Robidoux, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Hit paper breakdown → | 1998 | 4503 |
| 2 | Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Hit paper breakdown → | 1998 | 1788 |
| 3 | Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. Hit paper breakdown → | 1997 | 1465 |
| 4 | Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 Hit paper breakdown → | 2008 | 1435 |
| 5 | Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Hit paper breakdown → | 2010 | 1427 |
| 6 | A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors Hit paper breakdown → | 1989 | 1235 |
| 7 | Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study Hit paper breakdown → | 2005 | 1059 |
| 8 | Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Hit paper breakdown → | 2011 | 966 |
| 9 | 2007 | 856 | |
| 10 | Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-011 Hit paper breakdown → | 1988 | 811 |
| 11 | 2006 | 773 | |
| 12 | Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors Hit paper breakdown → | 1996 | 720 |
| 13 | Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study Hit paper breakdown → | 2014 | 663 |
| 14 | Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer Hit paper breakdown → | 2010 | 529 |
| 15 | 2005 | 427 | |
| 16 | 2012 | 370 | |
| 17 | 2019 | 326 | |
| 18 | 2013 | 311 | |
| 19 | 2011 | 273 | |
| 20 | 2008 | 266 |
About André Robidoux
André Robidoux is a scholar working on Cancer Research, Oncology, Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 110 papers that have together received 24k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (55 papers), BRCA gene mutations in cancer (16 papers), Cancer Risks and Factors (8 papers), Cancer survivorship and care (7 papers), Breast Lesions and Carcinomas (7 papers), HER2/EGFR in Cancer Research (7 papers), Bone health and treatments (5 papers) and Economic and Financial Impacts of Cancer (4 papers). The work is most often cited by research in Cancer Research (11.7k citations), Oncology (5.5k citations), Genetics (3.7k citations), Pathology and Forensic Medicine (1.7k citations) and Internal Medicine (201 citations). André Robidoux has collaborated with scholars based in Canada, United States and Switzerland. Frequent co-authors include Norman Wolmark, Donald Lawrence Wickerham, Bernard Fisher, Joseph P. Costantino, Richard G. Margolese, James N. Atkins, Eleftherios P. Mamounas, Sam Wieand, Victor G. Vogel and Maureen T. Kavanah. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, The Lancet Oncology, JNCI Journal of the National Cancer Institute and Clinical Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.